Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by New York State Teachers Retirement System

New York State Teachers Retirement System reduced its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 97,811 shares of the biopharmaceutical company’s stock after selling 2,616 shares during the quarter. New York State Teachers Retirement System’s holdings in Regeneron Pharmaceuticals were worth $69,674,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of REGN. Mizuho Securities USA LLC boosted its position in Regeneron Pharmaceuticals by 625.5% during the third quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company’s stock worth $62,382,000 after purchasing an additional 51,162 shares in the last quarter. Principal Financial Group Inc. raised its holdings in Regeneron Pharmaceuticals by 1.7% in the third quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company’s stock valued at $181,961,000 after acquiring an additional 2,828 shares in the last quarter. Simplify Asset Management Inc. lifted its stake in Regeneron Pharmaceuticals by 50.8% in the third quarter. Simplify Asset Management Inc. now owns 9,591 shares of the biopharmaceutical company’s stock worth $10,082,000 after acquiring an additional 3,231 shares during the last quarter. Golden State Equity Partners grew its holdings in Regeneron Pharmaceuticals by 1,479.1% during the 4th quarter. Golden State Equity Partners now owns 1,358 shares of the biopharmaceutical company’s stock worth $967,000 after acquiring an additional 1,272 shares in the last quarter. Finally, Catalytic Wealth RIA LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at approximately $1,334,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $674.27 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 4.46. The business has a 50 day simple moving average of $710.88 and a 200-day simple moving average of $901.80. Regeneron Pharmaceuticals, Inc. has a 12 month low of $642.00 and a 12 month high of $1,211.20. The stock has a market capitalization of $74.10 billion, a PE ratio of 17.61, a price-to-earnings-growth ratio of 2.38 and a beta of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.79 billion for the quarter, compared to analysts’ expectations of $3.76 billion. During the same period in the previous year, the company posted $11.86 EPS. Regeneron Pharmaceuticals’s revenue was up 10.3% compared to the same quarter last year. Equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 36.67 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be given a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.52%. The ex-dividend date of this dividend is Thursday, February 20th.

Analysts Set New Price Targets

Several research firms have recently issued reports on REGN. Morgan Stanley decreased their price objective on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. UBS Group downgraded Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $1,130.00 to $738.00 in a report on Thursday, January 16th. Royal Bank of Canada dropped their price objective on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Wolfe Research assumed coverage on Regeneron Pharmaceuticals in a research report on Friday, November 15th. They set an “outperform” rating and a $1,150.00 target price on the stock. Finally, Bank of America reaffirmed an “underperform” rating and issued a $565.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $973.13.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.